Abstract
Human antithrombin (AT) has two isoforms of which the predominant α-form is glycosylated on all four possible glycosylation sites and the lower abundant β-isoform lacks the oligosaccharide on Asn135. The main oligosaccharide structure of human AT consists of biantennary complex-type oligosaccharides lacking a core fucose. Generally, Chinese hamster ovary (CHO) cells produce recombinant human AT (rhAT) with core-fucosylated oligosaccharides. However, rhAT lacking core-fucose oligosaccharides can be produced by POTELLIGENT® technology, which uses FUT8 knockout CHO cells in production. The rhAT has more variable glycan structures, such as tetra-antennary complex type, highmannose type, and mannose 6-phosphate species as minor components compared to plasma-derived human AT (phAT). In addition, the site-specific glycan profile was different between two ATs. We evaluated the effect of these properties on efficacy and safety based on a comparison of rhAT made by that technology with phAT in terms of their respective oligosaccharide structures, site-specific oligosaccharide profiles, and the ratio of α- and β-forms. Although some structural differences were found between the rhAT and phAT, we concluded that these differences have no significant effect on the efficacy and safety of rhAT.
Similar content being viewed by others
References
J. Travis and G. S. Salvesen, Annu. Rev. Biochem., 1983, 52, 655.
D. Menache, Semin. Hematol., 1991, 28, 1.
D. Menache, B. J. Grossman, and C. M. Jackson, Transfusion, 1992, 32, 580.
B. Lahiri, A. Bagdasarian, B. Mitchell, R. C. Talamo, and R. W. Colman, Arch. Biochem. Biophys., 1976, 175, 737.
R. D. Rosenberg, K. A. Bauer, and J. A. Marcum, J. Med., 1985, 16, 351.
G. Murano, L. Williams, M. Miller-Andersson, D. L. Aronson, and C. King, Thromb. Res., 1980, 18, 259.
L. E. Franzén, S. Svensson, and O. Larm, J. Biol. Chem., 1980, 255, 5090.
U. M. Demelbauer, A. Plematl, L. Kremser, G. Allmaier, D. Josic, and A. Rizzi, Electrophoresis, 2004, 25, 2026.
B. Turk, I. Brieditis, S. C. Bock, S. T. Olson, and I. Björk, Biochemistry, 1997, 36, 6682.
S. O. Brennan, P. M. George, and R. E. Jordan, FEBS Lett., 1987, 219, 431.
E. Bause and G. Legler, Biochem. J., 1981, 195, 639.
V. Picard, E. Ersdal-Badju, and S. C. Bock, Biochemistry, 1995, 34, 8433.
I. V. Turko, B. Fan, and P. G. Gettins, FEBS Lett., 1993, 335, 9.
C. B. Peterson and M. N. Blackburn, J. Biol. Chem., 1985, 260, 610.
S. O. Brennan, P. M. George, and R. E. Jordan, FEBS Lett., 1987, 219, 431.
S. Frebelius, S. Isaksson, and J. Swedenborg, Arterioscler. Thromb. Vasc. Biol., 1996, 16, 1292.
N. Yamane-Ohnuki, S. Kinoshita, M. Inoue-Urakubo, M. Kusunoki, S. Iida, R. Nakano, M. Wakitani, R. Niwa, M. Sakurada, K. Uchida, K. Shitara, and M. Satoh, Biotechnol. Bioeng., 2004, 87, 614.
A. Beck and J. M. Reichert, mAbs, 2012, 4, 419.
B. Fan, B. C. Crews, I. V. Turko, J. Choay, G. Zettlmeissl, and P. Gettins, J. Biol. Chem., 1993, 268, 17588.
L. Garone, T. Edmunds, E. Hanson, R. Bernasconi, J. A. Huntington, J. L. Meagher, B. Fan, and P. G. Gettins, Biochemistry, 1996, 35, 8881.
S. Mochizuki, K. Miyano, M. Kondo, M. Hirose, A. Masaki, and H. Ohi, Protein Expr. Purif., 2005, 41, 323.
S. T. Olson, A. M. Frances-Chmura, R. Swanson, I. Björk, and G. Zettlmeissl, Arch. Biochem. Biophys., 1997, 341, 212.
S. Endo and R. Shimazaki, J. Intensive Care, 2018, 6, 75.
T. Watanabe, N. Inoue, T. Kutsukake, S. Matsuki, and M. Takeuchi, Biol. Pharm. Bull., 2000, 23, 269.
A. Hasilik, U. Klein, A. Waheed, G. Strecker, and K. von Figura, Proc. Natl. Acad. Sci. U. S. A., 1980, 77, 7074.
A. Varki, W. Sherman, and S. Kornfeld, Arch. Biochem. Biophys., 1983, 222, 145.
M. Kobayashi, H. Hoshino, J. Masumoto, M. Fukushima, K. Suzawa, S. Kageyama, M. Suzuki, H. Ohtani, M. Fukuda, and J. Nakayama, Inflamm. Bowel. Dis., 2009, 15, 697.
H. Kawashima, B. Petryniak, N. Hiraoka, J. Mitoma, V. Huckaby, J. Nakayama, K. Uchimura, K. Kadomatsu, T. Muramatsu, J. B. Lowe, and M. Fukuda, Nat. Immunol., 2005, 6, 1096.
L. E. Franzén, S. Svensson, and O. Larm, J. Biol. Chem., 1980, 255, 5090.
M. Takeuchi, S. Takasaki, H. Miyazaki, T. Kato, S. Hoshi, N. Kochibe, and A. Kobata, J. Biol. Chem., 1988, 263, 3657.
C. Y. Chung, B. Yin, Q. Qang, K. Y. Chuang, J. H. Chu, and M. J. Betenbaugh, Biochem. Biophys. Res. Commun., 2015, 463, 211.
S. K. Singh, J. Pharm. Sci., 2011, 100, 354.
T. Kizhner, Y. Azulay, M. Hainrichson, Y. Tekoah, G. Arvatz, A. Shulman, I. Ruderfer, D. Aviezer, and Y. Shaaltiel, Mol. Genet. Metab., 2015, 114, 259.
F. Clerc, K. R. Reiding, B. C. Jansen, G. S. Kammeijer, A. Bondt, and M. Wuhrer, Glycoconj. J., 2016, 33, 309.
F. N. Lamari, A. D. Theocharis, A. P. Asimakopoulou, C. J. Malavaki, and N. K. Karamanos, Biomed. Chromatogr., 2006, 20, 539.
H. Kawashima and M. Fukuda, Ann. N. Y. Acad. Sci., 2012, 1253, 112.
U. M. Demelbauer, A. Plematl, D. Josic, G. Allmaier, and A. Rizzi, J. Chromatogr. A, 2005, 1080, 15.
U. M. Demelbauer, M. Zehl, A. Plematl, G. Allmaier, and A. Rizzi, Rapid Commun. Mass Spectrom., 2004, 18, 1575.
A. Plematl, U. M. Demelbauer, D. Josic, and A. Rizzi, Proteomics, 2005, 5, 4025.
A. J. McCoy, X. Y. Pei, R. Skinner, J. P. Abrahams, and R. W. Carrell, J. Mol. Biol., 2003, 326, 823.
J. C. Egrie and J. K. Browne, Br. J. Cancer, 2001, 84, 3.
S. J. Lee, S. Evers, D. Roeder, A. F. Parlow, J. Risteli, L. Risteli, Y. C. Lee, T. Feizi, H. Langen, and M. C. Nussenzweig, Science, 2002, 295, 1898.
Y. Kanda, T. Yamada, K. Mori, A. Okazaki, M. Inoue, K. Kitajima-Miyama, R. Kuni-Kamochi, R. Nakano, K. Yano, S. Kakita, K. Shitara, and M. Satoh, Glycobiology, 2007, 17, 104.
Y. Mi, A. Lin, D. Fiete, L. Steirer, and J. U. Baenziger, J. Biol. Chem., 2014, 289, 12157.
T. Yamada, Y. Kanda, M. Takayama, A. Hashimoto, T. Sugihara, A. Satoh-Kubota, E. Suzuki-Takanami, K. Yano, S. Iida, and M. Satoh, Glycobiology, 2016, 26, 482.
H. Larsson, P. Akerud, K. Nordling, E. Raub-Segall, L. Claesson-Welsh, and I. Björk, J. Biol. Chem., 2001, 276, 11996.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yagi, Y., Okazaki, A., Endo, M. et al. A Comparison of the Oligosaccharide Structures of Antithrombin Derived from Plasma and Recombinant Using POTELLIGENT® Technology. ANAL. SCI. 35, 1333–1340 (2019). https://doi.org/10.2116/analsci.19P181
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2116/analsci.19P181